
Oncology NPs discuss new frontline options for metastatic triple-negative breast cancer, using cases to guide therapy choice and manage toxicities.

Oncology NPs discuss new frontline options for metastatic triple-negative breast cancer, using cases to guide therapy choice and manage toxicities.

Why first-line choices matter in metastatic TNBC: many miss second-line care, and new antibody-drug conjugates boost survival over chemo.